Cholinergic Agonists
Cholinergic agonists are parasympathomimetics that stimulate muscarinic receptors on the detrusor smooth muscle to enhance bladder contractility. Bethanechol chloride is the only FDA-approved cholinergic agonist for urologic use, indicated for acute postoperative or postpartum non-obstructive urinary retention and neurogenic atony of the bladder with retention. It continues to be prescribed — primarily by urologists (~92% of fills) — but the underlying clinical evidence is low-quality, and contemporary reviews regard muscarinic agonists as having limited efficacy and frequent adverse effects for detrusor underactivity.[1][2][3][4]
For the clinical condition this drug class targets, see Underactive Bladder. For the antimuscarinic side of the same receptor system used in storage / OAB, see Anticholinergics.
Pharmacologic Framework — Cholinergic Control of the Bladder
Muscarinic receptor physiology
Normal voiding is initiated by parasympathetic release of acetylcholine (ACh) from pelvic nerves onto the detrusor. The bladder's cholinergic system is more complex than simple "ACh causes contraction" — multiple receptor subtypes operate at multiple sites, which is part of why agonist therapy is unpredictable in practice.[5][6][7][8]
| Site / receptor | Role |
|---|---|
| M₃ — detrusor smooth muscle | Principal driver of direct contraction (PLC, voltage-gated Ca²⁺, Rho kinase) |
| M₂ — detrusor smooth muscle | Most abundant subtype (~80%); indirect / backup role; opposes β-adrenergic relaxation; gains importance with denervation and aging |
| M₁ — prejunctional nerve terminals | Facilitate ACh release (positive feedback) |
| M₄ — prejunctional nerve terminals | Inhibit ACh and noradrenaline release (negative feedback) |
| Urothelial muscarinic receptors | Stimulate ATP and NO release that modulates afferent activity and reflex voiding |
| Suburothelial interstitial cells | Express muscarinic receptors of unknown function |
This anatomic complexity explains why direct muscarinic agonists simultaneously stimulate contraction, modulate sensory pathways, and alter neurotransmitter release — and why their clinical effect on a clogged or weak bladder is far less reliable than benchtop pharmacology suggests.[5]
Two classes used (or studied) in urology
| Class | Agents | Mechanism |
|---|---|---|
| Direct muscarinic agonists | Bethanechol (FDA-approved); carbachol, pilocarpine (historical / non-urologic) | Direct muscarinic-receptor stimulation; resistant to cholinesterase[2][3][5] |
| Cholinesterase inhibitors (indirect) | Distigmine, neostigmine, pyridostigmine | Inhibit ACh breakdown → increased synaptic ACh[5][9][10][11][12][13][14] |
Bethanechol Chloride — the primary urologic agent
Pharmacology[2]
A synthetic choline ester structurally related to ACh with three useful properties:
- Cholinesterase-resistant — not hydrolyzed, giving a longer duration than ACh
- Muscarinic-selective — at therapeutic doses, nicotinic effects (ganglionic stimulation, skeletal muscle contraction) are minimal; muscarinic effects predominate
- Does not cross the blood–brain barrier — quaternary amine; no CNS effects
Pharmacokinetics:
- Oral — onset 30–90 min; peak 60–90 min; duration ~1 h (up to 6 h with large doses)
- SC — onset 5–15 min; peak 15–30 min; duration ~2 h
- SC is much more potent — 5 mg SC produces a faster and larger response than 50–200 mg oral, but oral has a longer duration
- Metabolic fate and excretion not fully elucidated
SC bethanechol is no longer commonly stocked in the US — the oral tablet is the practical formulation.
FDA-approved indications[2]
- Acute postoperative and postpartum non-obstructive (functional) urinary retention
- Neurogenic atony of the urinary bladder with retention
Dosing[2]
- Oral: 10–50 mg three or four times daily
- Titration: start 5–10 mg; repeat the same dose at hourly intervals until satisfactory response or a single 50 mg dose is reached
- Take on an empty stomach (1 h before or 2 h after meals) to limit nausea / vomiting
- Antidote for overdose: atropine sulfate 0.6 mg SC / IV; repeat every 2 h as needed
Contraindications[2]
The non-negotiable rule: bethanechol must never be used when bladder outlet obstruction is possible — if the sphincter does not relax as the detrusor contracts, urine is forced retrograde, producing vesicoureteral reflux and reflux infection. Other formal contraindications:
- Bladder outlet obstruction or any mechanical obstruction
- Recent bladder surgery or compromised bladder-wall integrity
- Recent GI surgery, resection / anastomosis, or obstruction
- Hyperthyroidism, peptic ulcer disease
- Latent or active asthma; COPD
- Pronounced bradycardia or hypotension
- Coronary artery disease
- Epilepsy, parkinsonism
- Marked vagotonia
- Spastic GI disorders, acute inflammatory GI lesions, peritonitis
Adverse effects[2]
Adverse effects are uncommon at oral therapeutic doses but common with parenteral or supratherapeutic dosing. The pattern is the classic muscarinic / SLUDGE response:
| Domain | Effects |
|---|---|
| GI | Nausea, vomiting, abdominal cramping, diarrhea, salivation, belching, borborygmi |
| Cardiovascular | Hypotension with reflex tachycardia, flushing, sweating |
| Respiratory | Bronchospasm, asthma exacerbation |
| Genitourinary | Urgency; reflux into the kidneys if used despite outlet obstruction |
| Eye | Lacrimation, miosis |
| Skin | Diaphoresis |
Severe overdose can produce circulatory collapse, sudden hypotension, syncope, or cholinergic crisis — managed with atropine 0.6 mg SC / IV repeated every 2 h as needed.[2]
Cholinesterase Inhibitors
Indirect cholinergic agents have been studied for detrusor underactivity, primarily in Japan and Europe; none is FDA-approved for urologic use in the US.[5][10][11][12][13][14]
| Agent | Status | Notes |
|---|---|---|
| Distigmine bromide | Used in Japan / Europe for atonic bladder | Long anticholinesterase action; potentiates ACh-induced detrusor contraction; risk of cholinergic crisis[11][12][13] |
| Neostigmine, pyridostigmine | Off-label / historical | Used briefly for postoperative ileus and atonic bladder; largely abandoned in urology |
| TAK-802 (investigational) | Selective AChE inhibitor | Improved urodynamic parameters in animal models; not in clinical use[14] |
In practice these agents are not part of contemporary US urologic prescribing.
Evidence Summary
| Setting | Evidence | Result |
|---|---|---|
| Postoperative urinary retention (any drug, any sex) | Cochrane review (Buckley & Lapitan)[9] | Insufficient evidence to support routine pharmacologic prophylaxis or treatment |
| Underactive bladder — direct muscarinic agonists ± AChE inhibitors | Systematic review and meta-analysis (Moro et al.)[3] | Statistical improvement in some urodynamic parameters; clinically modest; high adverse-event rate; evidence quality low |
| General lower-tract pharmacotherapy review | Abraham & Goldman update[10] | Muscarinic agonists have limited efficacy in detrusor underactivity; prescribing should be individualized |
| Detrusor underactivity overview | Drake et al. Nat Rev Urol[4] | No drug consistently restores normal voiding; bladder management (CIC, alpha-blocker for bladder neck) usually outperforms cholinergic agonists |
| Real-world prescribing | Gaitonde et al.[1] | Despite weak evidence, bethanechol continues to be prescribed mostly by urologists; ~92% of fills written by urology |
The pragmatic conclusion: bethanechol may help selected patients with truly atonic, non-obstructed bladders — particularly the immediate postoperative or postpartum setting — but should not be expected to "fix" detrusor underactivity, and should never be combined with an unrelieved outlet obstruction.[1][3][4]
Clinical Positioning
- Confirm non-obstructive retention before prescribing — exclude outlet obstruction (BPH, urethral stricture, bladder neck dysfunction) by exam, PVR, uroflow, and where indicated cystoscopy or RUG. Outlet obstruction is an absolute contraindication.[2]
- Manage outlet relaxation in parallel when functional bladder neck dysfunction or DSD coexists — alpha-blockers for bladder-neck, sphincter-directed therapy for DSD; cholinergic agonists alone are inadequate.[10]
- Acute postoperative / postpartum atony is the most defensible indication — short-term oral bethanechol while the bladder recovers, paired with clean intermittent catheterization as the workhorse drainage strategy.[2][9]
- CIC is the cornerstone of chronic detrusor underactivity — pharmacotherapy is adjunctive at best.[4]
- Avoid in older adults with cardiopulmonary disease — the AE profile (bronchospasm, bradycardia, hypotension, GI cramping) is particularly poorly tolerated.[2]
- Counsel about cholinergic side effects — flushing, sweating, salivation, abdominal cramps, diarrhea — and about taking on an empty stomach.[2]
Practical Pearls
- Outlet obstruction is the single most important rule-out before prescribing bethanechol — failure to do so produces vesicoureteral reflux and pyelonephritis[2]
- Effects are modest and inconsistent — set expectations accordingly with patients[1][3][4]
- Empty stomach dosing reduces GI side effects substantially[2]
- Atropine 0.6 mg SC / IV is the antidote for cholinergic crisis[2]
- CIC outperforms any cholinergic agonist for chronic atonic bladder management[4]
- Cholinesterase inhibitors are not part of US urologic practice — distigmine remains a Japanese / European option but is not commonly used[10][11][12]
See Also
- Underactive Bladder — clinical condition and management algorithm
- Voiding & Outlet pharmacology overview
- Anticholinergics — antagonists at the same receptor system
- Alpha-blockers — outlet-relaxation adjunct in functional retention
References
1. Gaitonde S, Malik RD, Christie AL, Zimmern PE. "Bethanechol: is it still being prescribed for bladder dysfunction in women?" Int J Clin Pract. 2019;73(8):e13248. doi:10.1111/ijcp.13248
2. US Food and Drug Administration. Bethanechol Chloride — prescribing information. Updated 2024-01-22.
3. Moro C, Phelps C, Veer V, et al. "The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis." Neurourol Urodyn. 2022;41(1):127–139. doi:10.1002/nau.24839
4. Drake MJ, Williams J, Bijos DA. "Voiding dysfunction due to detrusor underactivity: an overview." Nat Rev Urol. 2014;11(8):454–464. doi:10.1038/nrurol.2014.156
5. Sellers DJ, Chess-Williams R. "Muscarinic agonists and antagonists: effects on the urinary bladder." Handb Exp Pharmacol. 2012;(208):375–400. doi:10.1007/978-3-642-23274-9_16
6. Frazier EP, Peters SL, Braverman AS, Ruggieri MR, Michel MC. "Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors." Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4-6):449–462. doi:10.1007/s00210-007-0208-0
7. Choppin A, Eglen RM. "Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle." Br J Pharmacol. 2001;133(7):1035–1040. doi:10.1038/sj.bjp.0704165
8. Kullmann FA, Artim DE, Birder LA, de Groat WC. "Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity." J Neurosci. 2008;28(8):1977–1987. doi:10.1523/JNEUROSCI.4694-07.2008
9. Buckley BS, Lapitan MC. "Drugs for treatment of urinary retention after surgery in adults." Cochrane Database Syst Rev. 2010;(10):CD008023. doi:10.1002/14651858.CD008023.pub2
10. Abraham N, Goldman HB. "An update on the pharmacotherapy for lower urinary tract dysfunction." Expert Opin Pharmacother. 2015;16(1):79–93. doi:10.1517/14656566.2015.977253
11. Obara K, Kobayashi Y, Chino D, Tanaka Y. "Effect of distigmine on the contractile response of guinea pig urinary bladder to electrical field stimulation." Eur J Pharmacol. 2017;809:209–214. doi:10.1016/j.ejphar.2017.05.031
12. Obara K, Ogawa T, Chino D, Tanaka Y. "The long-lasting enhancing effect of distigmine on acetylcholine-induced contraction of guinea pig detrusor smooth muscle correlates with its anticholinesterase activity." Biol Pharm Bull. 2017;40(7):1092–1100. doi:10.1248/bpb.b17-00175
13. Obara K, Tanaka Y. "Effects of distigmine on the mechanical activity of urinary bladder smooth muscle." Biol Pharm Bull. 2019;42(7):1064–1068. doi:10.1248/bpb.b19-00201
14. Nagabukuro H, Okanishi S, Doi T. "Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs." Eur J Pharmacol. 2004;494(2-3):225–232. doi:10.1016/j.ejphar.2004.05.007